These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
495 related articles for article (PubMed ID: 21415578)
21. Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk. Wu Z; Gao J; Zhuang W; Yang J; Guo W J Cancer Res Ther; 2022 Apr; 18(2):345-351. PubMed ID: 35645099 [TBL] [Abstract][Full Text] [Related]
22. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients. Gomes AS; Monteleone PA; Sayre JW; Finn RS; Sadeghi S; Tong MJ; Britten CD; Busuttil RW AJR Am J Roentgenol; 2017 Oct; 209(4):722-732. PubMed ID: 28705059 [TBL] [Abstract][Full Text] [Related]
23. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345 [TBL] [Abstract][Full Text] [Related]
24. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849 [TBL] [Abstract][Full Text] [Related]
25. Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-A Retrospective Study. Chen Y; Jia L; Li Y; Cui W; Wang J; Zhang C; Bian C; Wang Z; Lin D; Luo T Ann Surg Oncol; 2024 Nov; 31(12):7860-7869. PubMed ID: 39090499 [TBL] [Abstract][Full Text] [Related]
26. Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma. Lopez RR; Pan SH; Hoffman AL; Ramirez C; Rojter SE; Ramos H; McMonigle M; Lois J Arch Surg; 2002 Jun; 137(6):653-7; discussion 657-8. PubMed ID: 12049535 [TBL] [Abstract][Full Text] [Related]
27. Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. Li S; Lyu N; Han X; Li J; Lai J; He M; Deng H; Shi M; Wang H; Zhao M J Vasc Interv Radiol; 2021 Sep; 32(9):1267-1276.e1. PubMed ID: 34166806 [TBL] [Abstract][Full Text] [Related]
28. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients. Gao S; Zhang PJ; Guo JH; Chen H; Xu HF; Liu P; Yang RJ; Zhu X World J Gastroenterol; 2015 Sep; 21(36):10443-52. PubMed ID: 26420971 [TBL] [Abstract][Full Text] [Related]
29. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Choi JH; Chung WJ; Bae SH; Song DS; Song MJ; Kim YS; Yim HJ; Jung YK; Suh SJ; Park JY; Kim DY; Kim SU; Cho SB Cancer Chemother Pharmacol; 2018 Sep; 82(3):469-478. PubMed ID: 29982870 [TBL] [Abstract][Full Text] [Related]
30. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. Kodama K; Kawaoka T; Aikata H; Uchikawa S; Nishida Y; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Kimura T; Nagata Y; Chayama K Oncology; 2018; 94(4):215-222. PubMed ID: 29428943 [TBL] [Abstract][Full Text] [Related]
31. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials. Huang Y; Zhang L; He M; Lai Z; Bu X; Wen D; Li Q; Xu L; Wei W; Zhang Y; Zhou Z; Chen M; Guo R; Shi M; Kan A Technol Cancer Res Treat; 2022; 21():15330338221117389. PubMed ID: 36529949 [No Abstract] [Full Text] [Related]
32. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma. Arabi M; BenMousa A; Bzeizi K; Garad F; Ahmed I; Al-Otaibi M Saudi J Gastroenterol; 2015; 21(3):175-80. PubMed ID: 26021777 [TBL] [Abstract][Full Text] [Related]
33. Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. Song DS; Bae SH; Song MJ; Lee SW; Kim HY; Lee YJ; Oh JS; Chun HJ; Lee HG; Choi JY; Yoon SK World J Gastroenterol; 2013 Aug; 19(29):4679-88. PubMed ID: 23922465 [TBL] [Abstract][Full Text] [Related]
34. Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study. Tang C; Shen J; Feng W; Bao Y; Dong X; Dai Y; Zheng Y; Zhang J Medicine (Baltimore); 2016 May; 95(20):e3754. PubMed ID: 27196501 [TBL] [Abstract][Full Text] [Related]
35. Hepatic arterial infusion chemotherapy vs transcatheter arterial embolization for patients with huge unresectable hepatocellular carcinoma. Tsai WL; Sun WC; Chen WC; Chiang CL; Lin HS; Liang HL; Cheng JS Medicine (Baltimore); 2020 Aug; 99(32):e21489. PubMed ID: 32769883 [TBL] [Abstract][Full Text] [Related]
36. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC. Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737 [TBL] [Abstract][Full Text] [Related]
37. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival. Kirchhoff TD; Bleck JS; Dettmer A; Chavan A; Rosenthal H; Merkesdal S; Frericks B; Zender L; Malek NP; Greten TF; Kubicka S; Manns MP; Galanski M Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):259-66. PubMed ID: 17548248 [TBL] [Abstract][Full Text] [Related]
38. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. Mabed M; Esmaeel M; El-Khodary T; Awad M; Amer T Eur J Cancer Care (Engl); 2009 Sep; 18(5):492-9. PubMed ID: 19453695 [TBL] [Abstract][Full Text] [Related]
39. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma]. Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802 [TBL] [Abstract][Full Text] [Related]
40. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization, potential conversion therapies for single huge hepatocellular carcinoma: a retrospective comparison study. Deng M; Cai H; He B; Guan R; Lee C; Guo R Int J Surg; 2023 Nov; 109(11):3303-3311. PubMed ID: 37578432 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]